LPIXEL Inc.is pleased to announce that it has agreed to sell the mammography diagnostic support AI technology developed by FathomX Pte Ltd through the “EIRL AI Partner Program,” which supports partner companies in the commercialization and sales of imaging diagnostic support AI products.
LPIXEL aims to expand the scope of imaging diagnostic support AI to include a wider range of diseases and areas by collaborating with partner companies.

Background:
FathomX is an AI startup specialized in breast cancer, spun off from the National University of Singapore in 2019, co-developing AI based on mammography—the global gold standard for breast cancer screening. The AI solution is highly accurate even for dense breasts, which are common among Asian women, and is already regulatory approved in seven countries and regions across Asia. These AI technologies for imaging diagnostics face numerous challenges before they can be utilized in medical institutions, even after going through the necessary procedures for commercialization. For example, connecting to existing medical IT systems and building sales networks requires customization for each medical institution.
On the other hand, LPIXEL , with the mission of “AI for Healthcare, Ensuring a Healthy Future for All,” has been deploying its EIRL series of imaging diagnostic support AI, focusing on major causes of death such as lung cancer and colorectal cancer. LPIXEL has installed its products in over 900 medical facilities in japan . Early detection of cancer through various tests is crucial, and the risk of missing diagnoses is high, making imaging diagnostic AI a promising area for support. Economically, the total cost of cancer in society is estimated to be around 2.86 trillion yen, with lung cancer in men accounting for the largest economic loss (approximately 92.1 billion yen) and breast cancer in women accounting for approximately 232.6 billion yen . From this perspective, there is significant potential for imaging diagnostic AI to contribute to society. In addition to improving the performance of existing products, expanding the target areas is also essential.

Sales Partnership through the “EIRL AI Partner Program”
As a front-runner in diagnostic support AI in Japan, LPIXEL has established a comprehensive system for product planning, data collection, development, regulatory approval, and sales, having obtained regulatory approvals and certifications for nine products to date.
In January 2024, LPIXEL announced the launch of the “EIRL AI Partner Program”, which leverages its in-house expertise to support partner companies in product development and sales. By integrating the diagnostic support AI technology developed by FathomX into the EIRL AI Platform, LPIXEL will enable connection with multiple major domestic PACS (medical imaging management system) manufacturers with which it has established connectivity. Additionally, by offering this technology alongside the existing EIRL series, which targets the chest and head, LPIXEL aims to provide comprehensive support for imaging diagnostics in health checkups, such as in human dock programs.